Advertisement


Tony S.K. Mok, MD, on NSCLC: Adagrasib vs Docetaxel in KRAS G12C–Mutated Disease

2024 ASCO Annual Meeting

Advertisement

Tony S.K. Mok, MD, of The Chinese University of Hong Kong, discusses phase III findings from the KRYSTAL-12 study, which showed that adagrasib improved progression-free survival and overall response rate over docetaxel in patients with locally advanced or metastatic non–small cell lung cancer harboring a KRAS G12C mutation who had previously received a platinum-based chemotherapy with anti–PD-(L)1 treatment.



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Crystal-XII is a randomized phase three study that compare adagrasib with docetaxel in previously treated non-small cell lung cancer, that harbored KRAS-G2LC mutation. Now this study is important. Now, as you probably know, KRAS-G2LC accounted for about 14% of all lung adenocarcinoma. And then the adagrasib, which is a covalent bonded inhibitor of the KRAS-G2LC, as demonstrated in the early phase two data, that there is actually promising response rate, progression-free survival and over-survival. And also NCCN had approved that this is a category 2A agent for patient with this mutation, and brain metastasis. However, we still need to prove it with the randomized study, and is the time that we can share with you the result. So a bit of the design. This is designed to enroll the patient with the KRAS-G2LC stage four. The patient can receive chemotherapy, and also immunotherapy either concurrently or sequentially. It's a randomized in a two-to-one fashion, total above 453 patient. Now with that, there is actually, the patient actually was able to dispose, and majority of the patient received the targeted drug, meaning at aggressive of 99% of patient, and the dosage absolute arm is about 92% patient. And overall, the progression pre-survival is much improved, with the actually median of 5.5 versus, 3.8 months, hazard ratio 0.58. And also there is a difference in the response rate. 32% versus 9%, and this is also translated into a duration of response of about 8.4 months versus about 5.3 months. There's another feature that's important, which is the intracranial response. So for a patient with the known brain metastasis, we have a intracranial response rate of 24% versus about 11%. Safety wise, actually the most common toxicity is diarrhea. And then with this, actually the patient is mostly grade one and two. And also there's some nausea and vomiting, which is actually well controlled. One toxicity that's not so clear is that there's a slight elevation of the blood creatinine. However, most of this, patient will be reversible upon c-section of the drug. So as a conclusion, I think the Crystal-12 study had confirmed the role of the adagrasib as a second line therapy for patient with the lung cancer, with the KRAS-G2LC, after failing the chemotherapy and immunotherapy. In the future, there is also the Crystal-7 study, which actually put adagrasib in the first line. It will be in combination with pembrolizumab, comparing to pembrolizumab alone in patient with actually a PTPS score of over 50%.

Related Videos

Breast Cancer

Pierfranco Conte, MD, on Early-Stage Triple-Negative Breast Cancer: Trial Update on Avelumab as Adjuvant Treatment

Pierfranco Conte, MD, of the University of Padua, discusses phase III findings from the A-BRAVE trial, which was designed to evaluate the efficacy of avelumab, an anti–PD-L1 antibody, as adjuvant treatment for patients with early-stage triple-negative breast cancer who are at high risk (LBA500).

Lymphoma

Peter Riedell, MD, on DLBCL: Expert Commentary on Data From the ECHELON-3 Study

Peter Riedell, MD, of The University of Chicago, discusses phase III findings on the regimen of brentuximab vedotin in combination with lenalidomide and rituximab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This therapy demonstrated a survival advantage in the third-line setting, but as this is an interim analysis, questions remain regarding long-term safety and duration of response, according to Dr. Riedell (Abstract LBA7005).

Leukemia

Yucai Wang, MD, PhD, on Richter Transformation of CLL: Findings on Combination Therapy With an Immune Checkpoint Inhibitor

Yucai Wang, MD, PhD, of the Mayo Clinic, discusses the increased efficacy of combination therapy with pembrolizumab plus a BCR kinase inhibitor compared with pembrolizumab alone in patients with Richter transformation of chronic lymphocytic leukemia (CLL; Abstract 7050).

Multiple Myeloma

Claudio Cerchione, MD, PhD, on Staging Multiple Myeloma: New Findings on FDG PET/CT Scans and Whole-Body MRI

Claudio Cerchione, MD, PhD, of Italy’s Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, discusses preliminary findings from a prospective trial suggesting that by adding whole-body MRI to fludeoxyglucose-18 (FDG) PET/CT scans, clinicians may detect bone lesions earlier and more accurately in patients with either newly diagnosed or relapsed multiple myeloma, thus translating into potentially better outcomes (Abstract 7512).

Multiple Myeloma

Amrita Y. Krishnan, MD, and Paula Rodríguez-Otero, MD, PhD, on Multiple Myeloma: Findings From the PERSEUS Trial on a Regimen for Transplant-Eligible Patients

Amrita Y. Krishnan, MD, of the City of Hope Cancer Center, and Paula Rodríguez-Otero, MD, PhD, of Spain’s Cancer Center Clínica Universidad de Navarra, discuss data that appear to further support daratumumab plus bortezomib, lenalidomide, and dexamethasone as a new standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (Abstract 7502).

Advertisement

Advertisement




Advertisement